Septerna (NASDAQ:SEPN) Cut to Buy at Wall Street Zen

Wall Street Zen downgraded shares of Septerna (NASDAQ:SEPN) from a strong-buy rating to a buy rating in a research note released on Saturday morning.

Several other research firms have also recently issued reports on SEPN. Truist Financial initiated coverage on Septerna in a research note on Monday, December 15th. They set a “buy” rating and a $34.00 target price on the stock. Raymond James Financial started coverage on shares of Septerna in a report on Friday, December 19th. They issued a “strong-buy” rating and a $38.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Septerna in a research report on Wednesday, October 8th. HC Wainwright boosted their price target on shares of Septerna from $26.00 to $30.00 and gave the company a “buy” rating in a research report on Tuesday, November 11th. Finally, Jones Trading began coverage on shares of Septerna in a report on Tuesday, December 23rd. They issued a “buy” rating and a $43.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $33.00.

Septerna Trading Down 1.7%

Shares of NASDAQ:SEPN opened at $24.88 on Friday. The company has a market cap of $1.11 billion, a price-to-earnings ratio of -16.48 and a beta of 3.85. Septerna has a 12 month low of $4.17 and a 12 month high of $30.50. The company has a 50-day moving average price of $25.49 and a 200-day moving average price of $18.89.

Septerna (NASDAQ:SEPN) last announced its quarterly earnings results on Monday, November 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.28). The business had revenue of $21.50 million for the quarter, compared to analysts’ expectations of $24.50 million. Septerna had a negative net margin of 266.77% and a negative return on equity of 17.98%. As a group, research analysts forecast that Septerna will post -7.11 EPS for the current fiscal year.

Insiders Place Their Bets

In other Septerna news, SVP Daniel D. Long sold 3,501 shares of the firm’s stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $18.06, for a total transaction of $63,228.06. Following the completion of the transaction, the senior vice president owned 92,911 shares of the company’s stock, valued at approximately $1,677,972.66. This trade represents a 3.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Universal Beteiligungs und Servicegesellschaft mbH grew its stake in shares of Septerna by 116.7% in the second quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 222,702 shares of the company’s stock worth $2,354,000 after acquiring an additional 119,953 shares during the last quarter. Boothbay Fund Management LLC bought a new position in Septerna in the 2nd quarter worth about $255,000. PharVision Advisers LLC grew its position in Septerna by 17.5% during the 3rd quarter. PharVision Advisers LLC now owns 11,932 shares of the company’s stock valued at $224,000 after purchasing an additional 1,780 shares during the last quarter. Rhumbline Advisers grew its position in Septerna by 16.6% during the 1st quarter. Rhumbline Advisers now owns 23,318 shares of the company’s stock valued at $135,000 after purchasing an additional 3,323 shares during the last quarter. Finally, CW Advisors LLC bought a new stake in Septerna during the 2nd quarter valued at about $133,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.